MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
出版年份 2021 全文链接
标题
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
作者
关键词
-
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-17
DOI
10.1186/s10194-021-01267-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
- (2020) Hong Deng et al. BMC Neurology
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Erenumab efficacy in highly resistant chronic migraine: a real-life study
- (2020) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience
- (2020) Caterina Disco et al. NEUROLOGICAL SCIENCES
- One year experience with erenumab: real-life data in 30 consecutive patients
- (2020) Angelo Ranieri et al. NEUROLOGICAL SCIENCES
- Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
- (2020) Eleonora Matteo et al. NEUROLOGICAL SCIENCES
- Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study
- (2020) Francesca Schiano di Cola et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019
- (2020) T. J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab: from scientific evidence to clinical practice—the first Italian real-life data
- (2019) Piero Barbanti et al. NEUROLOGICAL SCIENCES
- Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
- (2019) Simona Lattanzi et al. DRUGS
- Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials
- (2019) Da Xu et al. CEPHALALGIA
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
- (2019) Messoud Ashina et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
- (2019) Messoud Ashina et al. CEPHALALGIA
- The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
- (2019) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Targeting calcitonin gene-related peptide: a new era in migraine therapy
- (2019) Andrew Charles et al. LANCET
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
- (2018) Cristina Tassorelli et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
- (2018) Yuhan Zhu et al. NEUROLOGICAL SCIENCES
- Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine
- (2018) Stephen D. Silberstein et al. HEADACHE
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
- (2017) Min Hou et al. JOURNAL OF HEADACHE AND PAIN
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- CGRP in human models of primary headaches
- (2016) Håkan Ashina et al. CEPHALALGIA
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine
- (2014) Eva Cernuda-Morollón et al. HEADACHE
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Adherence with Migraine Prophylaxis in Clinical Practice
- (2012) Ariel Berger et al. Pain Practice
- Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
- (2010) Jakob Møller Hansen et al. CEPHALALGIA
- The Use of Migraine Preventive Medications Among Patients with and without Migraine Headaches
- (2009) JE Lafata et al. CEPHALALGIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now